BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26030479)

  • 1. RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.
    Rhodes CJ; Im H; Cao A; Hennigs JK; Wang L; Sa S; Chen PI; Nickel NP; Miyagawa K; Hopper RK; Tojais NF; Li CG; Gu M; Spiekerkoetter E; Xian Z; Chen R; Zhao M; Kaschwich M; Del Rosario PA; Bernstein D; Zamanian RT; Wu JC; Snyder MP; Rabinovitch M
    Am J Respir Crit Care Med; 2015 Aug; 192(3):356-66. PubMed ID: 26030479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.
    Hopper RK; Moonen JR; Diebold I; Cao A; Rhodes CJ; Tojais NF; Hennigs JK; Gu M; Wang L; Rabinovitch M
    Circulation; 2016 May; 133(18):1783-94. PubMed ID: 27045138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
    Nickel NP; Spiekerkoetter E; Gu M; Li CG; Li H; Kaschwich M; Diebold I; Hennigs JK; Kim KY; Miyagawa K; Wang L; Cao A; Sa S; Jiang X; Stockstill RW; Nicolls MR; Zamanian RT; Bland RD; Rabinovitch M
    Am J Respir Crit Care Med; 2015 Jun; 191(11):1273-86. PubMed ID: 25853696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension.
    Dannewitz Prosseda S; Tian X; Kuramoto K; Boehm M; Sudheendra D; Miyagawa K; Zhang F; Solow-Cordero D; Saldivar JC; Austin ED; Loyd JE; Wheeler L; Andruska A; Donato M; Wang L; Huebner K; Metzger RJ; Khatri P; Spiekerkoetter E
    Am J Respir Crit Care Med; 2019 Jan; 199(1):83-98. PubMed ID: 30107138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cell Model of Pulmonary Arterial Hypertension Reveals Novel Gene Expression and Patient Specificity.
    Sa S; Gu M; Chappell J; Shao NY; Ameen M; Elliott KA; Li D; Grubert F; Li CG; Taylor S; Cao A; Ma Y; Fong R; Nguyen L; Wu JC; Snyder MP; Rabinovitch M
    Am J Respir Crit Care Med; 2017 Apr; 195(7):930-941. PubMed ID: 27779452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial
    Theilmann AL; Hawke LG; Hilton LR; Whitford MKM; Cole DV; Mackeil JL; Dunham-Snary KJ; Mewburn J; James PD; Maurice DH; Archer SL; Ormiston ML
    Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2605-2618. PubMed ID: 32998516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension.
    Prewitt AR; Ghose S; Frump AL; Datta A; Austin ED; Kenworthy AK; de Caestecker MP
    J Biol Chem; 2015 Jan; 290(2):960-71. PubMed ID: 25411245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
    Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
    Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y; Coleman L; Shi J; Beppu H; Sato K; Walsh K; Loscalzo J; Zhang YY
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H677-90. PubMed ID: 18552156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
    John A; Kizhakkedath P; Al-Gazali L; Ali BR
    Gene; 2015 Apr; 561(1):148-56. PubMed ID: 25688877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
    Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP
    Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
    Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
    Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
    Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
    J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
    Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
    Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2.
    Caruso P; Dunmore BJ; Schlosser K; Schoors S; Dos Santos C; Perez-Iratxeta C; Lavoie JR; Zhang H; Long L; Flockton AR; Frid MG; Upton PD; D'Alessandro A; Hadinnapola C; Kiskin FN; Taha M; Hurst LA; Ormiston ML; Hata A; Stenmark KR; Carmeliet P; Stewart DJ; Morrell NW
    Circulation; 2017 Dec; 136(25):2451-2467. PubMed ID: 28971999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.
    Frank DB; Lowery J; Anderson L; Brink M; Reese J; de Caestecker M
    Am J Physiol Lung Cell Mol Physiol; 2008 Jan; 294(1):L98-109. PubMed ID: 18024717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMPR2 gene delivery reduces mutation-related PAH and counteracts TGF-β-mediated pulmonary cell signalling.
    Feng F; Harper RL; Reynolds PN
    Respirology; 2016 Apr; 21(3):526-32. PubMed ID: 26689975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension.
    Han C; Hong KH; Kim YH; Kim MJ; Song C; Kim MJ; Kim SJ; Raizada MK; Oh SP
    Hypertension; 2013 May; 61(5):1044-52. PubMed ID: 23478097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.